Does Anthem Cover Liraglutide (Saxenda)?

Anthem's Official Position on Saxenda Coverage

Anthem Blue Cross Blue Shield does include liraglutide 3.0 mg (Saxenda) on select formularies, but the drug sits on specialty or non-preferred tiers for most plan designs. This means out-of-pocket costs are higher than generics, and the insurer requires clinical documentation before it approves a claim.

Anthem's clinical policy bulletin on anti-obesity medications follows closely the FDA's approved labeling for liraglutide 3.0 mg. The FDA approved Saxenda in December 2014 for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia [1]. Anthem's medical policies generally mirror these FDA-label criteria but add payer-specific requirements on top.

Coverage also depends on whether your plan is fully insured (Anthem bears the risk) or self-funded (your employer sets benefit terms with Anthem administering claims). Self-funded employer plans can exclude weight-loss medications entirely, even when Anthem's standard formulary would otherwise include Saxenda. Calling the member services number on the back of your Anthem card is the fastest way to confirm your specific benefit.

The Endocrine Society's 2015 clinical practice guideline recommends pharmacotherapy as an adjunct to lifestyle intervention for patients with BMI ≥30 or BMI ≥27 with comorbidities who have not achieved target weight loss through behavior change alone [2]. Anthem's criteria align with this guideline.

Prior Authorization Requirements for Saxenda Under Anthem

Nearly every Anthem plan that covers Saxenda requires prior authorization (PA). Your prescribing clinician must submit clinical documentation proving medical necessity before the pharmacy will fill the prescription at the insured rate.

The standard PA criteria across most Anthem commercial plans include the following. The patient must have a BMI of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnea. The patient must have participated in a structured lifestyle modification program (diet plus exercise counseling) for a minimum of three months, sometimes six months, without reaching a target of 5% total body weight loss [3]. The prescriber must document baseline weight, height, BMI, and the specific comorbidity being treated. Some Anthem plans also require step therapy, meaning the patient must first try and fail a less expensive weight-loss medication such as phentermine or phentermine-topiramate (Qsymia) before Saxenda will be authorized.

Dr. Scott Isaacs, an endocrinologist and clinical faculty member at Emory University School of Medicine, has noted: "Insurance barriers remain the single biggest obstacle to anti-obesity medication access. Patients who meet every clinical criterion still face denials because payers classify obesity treatment as elective rather than medically necessary."

Anthem typically issues PA decisions within 72 hours for standard requests and within 24 hours for urgent requests. If approved, the authorization is usually valid for 6 to 12 months, after which the clinician must resubmit documentation showing continued medical necessity and at least 4% to 5% weight loss from baseline.

What Saxenda Costs With and Without Anthem Coverage

The retail price of Saxenda without insurance averages approximately $1,349.02 per month for the maintenance dose of 3.0 mg daily, according to pricing data from the FDA's drug approval package and pharmacy benchmarks [4]. That cost puts liraglutide out of reach for most patients paying cash.

With Anthem coverage and a successful prior authorization, the patient's cost drops substantially. Depending on plan design, expect a monthly copay between $30 and $150 on preferred-tier formularies, or a coinsurance rate of 25% to 50% on non-preferred specialty tiers. A 30% coinsurance on a $1,349 drug still leaves $405 per month out of pocket, which is why understanding your tier placement matters.

Novo Nordisk offers the Saxenda Savings Card for commercially insured patients, which can reduce the copay to as little as $25 per month for eligible patients. This card does not apply to government-funded insurance programs such as Medicare, Medicaid, or Tricare [5]. Patients whose Anthem plan is a Medicare Advantage product cannot use the manufacturer savings card.

A 2021 analysis published in Obesity found that only 11% of commercially insured patients prescribed anti-obesity medications actually filled the prescription when cost-sharing exceeded $100 per month, compared to 68% fill rates when cost-sharing was under $50 [6]. The financial barrier is measurable and large.

Which Anthem Plans Are Most Likely to Cover Saxenda

Coverage varies widely across Anthem's product lines. Not all plans are the same.

Anthem commercial PPO and HMO plans are the most likely to include Saxenda on formulary, though tier placement differs. Large employer group plans in states like California, Virginia, Ohio, and Georgia tend to carry broader obesity medication benefits because those states have enacted parity laws or employer mandates that discourage blanket exclusions of FDA-approved anti-obesity drugs.

Anthem Medicare Advantage plans present a more complex picture. Traditional Medicare Part D has historically excluded coverage of anti-obesity medications, but the Treat and Reduce Obesity Act and subsequent CMS guidance have been expanding coverage pathways [7]. Some Anthem Medicare Advantage plans now offer supplemental benefits that include weight management drugs. Check your plan's Evidence of Coverage document or call Anthem's Medicare Advantage pharmacy line to confirm.

Anthem Medicaid managed care plans vary by state. States like New York and California have expanded Medicaid formularies to include select GLP-1 receptor agonists for obesity, while other states exclude them entirely. The CDC's Behavioral Risk Factor Surveillance System data shows that states with the highest obesity prevalence often have the most restrictive Medicaid coverage for anti-obesity medications, creating a troubling inverse care law [8].

Anthem individual marketplace (ACA) plans typically follow the state benchmark formulary. If the benchmark plan in your state covers anti-obesity medications, your ACA plan through Anthem should as well. If not, these drugs are frequently excluded.

The Clinical Evidence Behind Saxenda That Supports Coverage

Anthem's coverage decisions are partly driven by the clinical trial data demonstrating liraglutide's efficacy for weight loss. The SCALE Obesity and Prediabetes trial (N=3,731) randomized adults with BMI ≥30 (or ≥27 with comorbidity) to liraglutide 3.0 mg daily or placebo, both with lifestyle intervention. At 56 weeks, the liraglutide group lost a mean of 8.0% of body weight compared to 2.6% in the placebo group (P<0.001) [9]. More than 63% of liraglutide-treated patients achieved at least 5% weight loss, and 33% achieved at least 10% weight loss.

The SCALE Diabetes trial (N=846) examined liraglutide 3.0 mg specifically in patients with type 2 diabetes and BMI ≥27. Participants on liraglutide lost 6.0% of body weight at 56 weeks versus 2.0% on placebo, with a significant reduction in HbA1c of 1.3 percentage points [10]. This dual benefit of weight loss and glycemic improvement strengthens the medical necessity argument for patients with both obesity and type 2 diabetes filing claims through Anthem.

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement recommends that insurers cover FDA-approved anti-obesity medications as part of a comprehensive obesity management strategy, citing a level of evidence that obesity is a chronic, relapsing disease requiring long-term pharmacological management [11].

Dr. Harold Bays, Chief Science Officer of the Obesity Medicine Association, has stated: "The evidence for GLP-1 receptor agonists in obesity treatment is as strong as the evidence for statins in hyperlipidemia. Denying coverage for these medications is inconsistent with modern evidence-based medicine."

How to Appeal an Anthem Denial for Saxenda

If Anthem denies your Saxenda prior authorization, you have a right to appeal. The appeals process involves structured steps that increase approval odds when done correctly.

Step 1: Review the denial letter. Anthem must provide a written explanation of the reason for denial. Common reasons include insufficient documentation of lifestyle modification, missing comorbidity documentation, or step therapy requirements not yet met.

Step 2: Gather supporting documentation. Your prescriber should compile medical records showing BMI history over at least 6 months, documentation of diet and exercise counseling (dates, providers, and outcomes), lab work confirming comorbidities (fasting glucose, lipid panel, sleep study results), and a letter of medical necessity explaining why Saxenda is appropriate and why alternatives are inadequate or contraindicated.

Step 3: Submit a formal internal appeal. Anthem allows at least one level of internal appeal. Include the prescriber's letter of medical necessity, relevant clinical trial citations (SCALE trials), and guideline references from the Endocrine Society and AACE.

Step 4: Request an external review if the internal appeal fails. Under the ACA, you have the right to an independent external review by a third-party reviewer not affiliated with Anthem [12]. External reviewers overturn a significant portion of medical necessity denials for anti-obesity medications.

A retrospective study published in the Journal of Managed Care & Specialty Pharmacy found that 52% of anti-obesity medication denials were overturned on first-level appeal when accompanied by a letter of medical necessity citing specific clinical trial data and guideline recommendations [13]. Persistence matters.

Alternatives If Anthem Does Not Cover Saxenda

If your Anthem plan excludes Saxenda or your appeal fails, several alternatives exist.

Semaglutide (Wegovy). Anthem formularies increasingly favor Wegovy over Saxenda because the STEP-1 trial (N=1,961) demonstrated superior efficacy, with semaglutide 2.4 mg producing 14.9% mean weight loss at 68 weeks compared to 2.4% for placebo [14]. Anthem may cover Wegovy under different PA criteria or at a better tier than Saxenda. Ask your prescriber to check.

Tirzepatide (Zepbound). This dual GIP/GLP-1 receptor agonist received FDA approval for chronic weight management in November 2023. The SURMOUNT-1 trial (N=2,539) showed mean weight loss of 20.9% at the highest dose (15 mg) over 72 weeks [15]. Some Anthem plans have added tirzepatide to formulary.

Phentermine-topiramate (Qsymia). Often available at a lower tier and without PA on Anthem plans, Qsymia is less expensive and may be an acceptable first step for patients who have not tried non-GLP-1 options.

Novo Nordisk Patient Assistance Program. Uninsured patients or those with commercial insurance who face prohibitive costs may qualify for Novo Nordisk's patient assistance program, which provides Saxenda at no cost to eligible individuals with household income below 400% of the federal poverty level [16].

Compounded liraglutide. Some compounding pharmacies produce liraglutide at lower cost, though the FDA has issued guidance warning about quality and safety concerns with compounded GLP-1 agonists [17]. Discuss risks with your prescriber before considering this option.

What Documentation Your Doctor Should Submit to Anthem

A clean, thorough prior authorization submission reduces denial rates significantly. Your prescriber should include specific elements in the PA request.

The submission should contain your current height, weight, and calculated BMI from the most recent office visit, along with BMI measurements from at least two prior visits spanning 3 to 6 months to demonstrate chronicity. Include a complete list of weight-related comorbidities with supporting lab values or diagnostic codes (ICD-10 codes E66.01 for morbid obesity, E11 for type 2 diabetes, I10 for hypertension). Attach documentation of structured lifestyle modification attempts, including dates of nutritional counseling visits, names of programs (e.g., registered dietitian visits, structured commercial programs like WW), and measurable outcomes showing insufficient weight loss.

If step therapy is required, document the specific medications tried, doses used, duration of therapy, and reason for discontinuation (lack of efficacy, adverse effects). Include relevant clinical guidelines from the Endocrine Society or AACE supporting the use of liraglutide in the patient's clinical context [2][11].

Prescribers who include all of these elements in the initial submission reduce the rate of administrative denials by eliminating the most common documentation gaps that trigger automatic rejections.